Tag Archives: EHA

June, 2018

June, 2016

October, 2015

  • 19 October

    Pfizer’s ALL Drug Receives Breakthrough Therapy Designation

    Pfizer Inc. today announced that investigational antibody-drug conjugate (ADC) inotuzumab ozogamicin received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for acute lymphoblastic leukemia (ALL). The Breakthrough Therapy designation was based on the results of the Phase 3 INO-VATE ALL trial, which enrolled 326 adult patients with …